people living with HIV lipid profile, protease inhibitors, second-line ART regimens, switching, dolutegravir
Conditions
Interventions
PLWH on PIs-based for 2nd line ART regimens switching to TAF/FTC/DTG in a single, once-daily tablet regimen
Treatment
People living with HIV (PLWH) who switched from PIs-based to DTG-based regimens
Sponsors
Faculty of Medicine, Chulalongkorn University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: People living with HIV Aged at least 18 years On PIs-based regimens as a second-line ART treatment Virologically suppressed in past 6 months
Exclusion criteria
Exclusion criteria: Previous exposure to any INSTIs Documented ASCVD or disease required lipid-lowering agent On lipid-lowering agent Pregnancy eGFR < 30 mL/min/1.73m2 Hypothyroidism Cirrhosis CTP B or C On thiazide, loop diuretic, glucocorticoids, calcineurin inhibitors, danazol, vitamin A Oral contraceptive pill Hormonal replacement therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LDL-cholesterol 24 weeks after switching from PIs-based regimens to DTG-based regimens group calculated LDL-cholesterol from lipid profile's blood test | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy 24 weeks after switching HIV-RNA and CD4 count from blood test,Other metabolic parameters 24 weeks after switching Fasting plasma glucose, total cholesterol, triglycerides, HDL-cholesterol from blood test,Body mass index 24 weeks after switching body weight and height measurement,Renal function 24 weeks after switching eGFR by creatinine from blood test,Depression score 24 weeks after switching Patient Health Questionnaire-9 | — |
Countries
Thailand
Contacts
Public ContactNatthapol Kiatkangwanchon
Chulalongkorn university
Outcome results
None listed